Oppenheimer Maintains Outperform Rating for Zura Bio, Lowers Price Target to $17.00

Oppenheimer has maintained its "Outperform" rating for Zura Bio (ZURA) but lowered its price target from $19 to $17, a 10.53% decrease. Analyst Jeff Jones made the decision, indicating continued confidence in Zura Bio's potential performance despite the lowered expectations. The one-year target price averages $13.14, with a high estimate of $26 and a low of $3, representing a 972.89% upside from the current price of $1.23. The average brokerage recommendation is 1.6, indicating an "Outperform" status.

Oppenheimer has revised its rating and price target for Zura Bio (ZURA), maintaining its "Outperform" status but lowering its price target from $19 to $17. This represents a 10.53% decrease. The decision was made by analyst Jeff Jones, who expressed continued confidence in Zura Bio's potential despite the adjustment. The one-year target price averages $13.14, with a high estimate of $26 and a low of $3, indicating a significant upside potential of 972.89% from the current price of $1.23. The average brokerage recommendation is 1.6, reinforcing the "Outperform" status.

Zura Bio, a clinical-stage biotechnology company, focuses on developing novel therapies for immune and inflammatory disorders. The company's lead candidate, zb-168, targets IL7rα pathways and shows promise in treating alopecia areata and other immune-mediated conditions. Recent financial results and corporate updates highlight Zura Bio's progress in advancing its pipeline and maintaining a strong cash position.

In Q1 2025, Zura Bio reported a net loss of $17.4 million, compared to $7.7 million in Q1 2024, while R&D expenses increased to $10.5 million from $3.6 million year-over-year. The company also announced plans to initiate Phase 2 trials for tibulizumab in systemic sclerosis and hidradenitis suppurativa, set to begin in Q2 2025. These developments underscore Zura Bio's commitment to advancing its pipeline and expanding its therapeutic portfolio.

The recent financial and operational updates, along with the company's participation in key investor conferences, demonstrate Zura Bio's strategic focus on clinical trial progress and regulatory milestones. The lowered price target and maintained "Outperform" rating reflect a balanced assessment of Zura Bio's potential and the market's expectations.

References:
[1] https://www.stocktitan.net/news/ZURA/
[2] https://quantisnow.com/company/ZURA